Role of PPARα/PGC-1α in doxorubicin induced mouse dilated cardio-myopathy

AIM: To investigate the changes of peroxisome proliferator-activated receptors (PPAR)α/peroxisome proliferator activated receptor coactivator 1 alpha (PGC-1α) in doxorubicin (DOX) induced dilated cardiomyopathy (DCM) and its effect on the energy metabolism and myocardial function in mice. METHODS: Forty mice were randomly divided into 4 groups: control group, DOX group, PPARα inhibitor group and PPARα agonist group. The DCM model was established by injection of DOX. The protein levels of PPARα/PGC-1α were detected. The PPARα inhibitor and PPARα agonist were used 2 weeks beforeinjection of DOX. The contents of adenine acid and phosphocreatine (Pcr) in the mitochondria were measured by high-performance liquid chromatography (HPLC). The ANT activity was analyzed by the atractyloside-inhibitor stop technique. The changes of the echocardiography and hemodynamics were also observed. RESULTS: DOX induced DCM model was successfully established. The protein levels of PPARα and PGC-1α in control group were significantly higher than those in DOX group (P<0.05). Both of the high-energy phosphate contents and the transport activity of ANT were decreased in DOX group (P<0.05), and the hemodynamic parameters were disordered (P<0.01). Compared with DOX group, PPARα inhibitor pre-treatment significantly reduced the PPARα/PGC-1α expression. Meanwhile, high-energy phosphate contents in the mitochondria and the ANT transport activity of the mitochondria decreased, as well as the left ventricular function (P<0.05). On the other hand, PPARα agonist significantly increased the expression of PPARα and PGC-1α, and improved the transport activity of ANT. In addition, the hemodynamic parameters were ameliorated, but the high-energy phosphate contents of the mitochondria did not significantly change. CONCLUSION: PPARα/PGC-1α plays an important role in the regulation of ANT transport activity in dilated cardiomyopathy induced by DOX, and the activation of PPARα/PGC-1α has protective effects on the DCM induced by DOX.     

Roles of atypical chemokine receptors in progression and metastasis of tumor

Chemokines and their receptors have been implicated mostly in tumor progression and metastasis. Atypical chemokine receptors (ACKRs) comprise a group of 7-transmembrane domain proteins structurally similar to G protein-coupled receptors. However, ACKRs do not induce classical signaling via the typical G protein-mediated pathways. ACKRs efficiently internalize the cognate chemokine ligands and act as scavengers instead. ACJRs are composed of at least 3 members of chemokine receptors:Duffy antigen receptor for chemokines (DARC, also known as ACKR1), D6 (also known as ACKR2) and ChemoCentryx chemokine receptor (CCX-CKR, also known as ACKR4). These receptors bind to and/or internalize their chemoattractant ligands without activating signal transduction cascades leading to cell migration. In this review, we summarize the recent progress regarding the roles of ACKRs in the progression and metastasis of tumor.     

Pharmacological and therapeutic targets for Δ9 tetrahydrocannabinol and cannabidiol

Summary Cannabis is the unique source of a set of at least 66 compounds known collectively as cannabinoids. Of these, most is known about the pharmacology of ⁹-tetrahydrocannabinol (⁹-THC), the main psychoactive constituent of cannabis, and about cannabidiol (CBD), which lacks psychoactivity. Accordingly, this paper focuses on the pharmacological and therapeutic targets of these two cannabinoids. Many of the effects of ⁹-THC are mediated by cannabinoid receptors of which at least two types, CB₁ and CB₂, are present in mammalian tissues. Endogenous agonists for cannabinoid receptors have also been discovered. CB₁ receptors are present at the terminals of central and peripheral neurones, where they modulate transmitter release. They also exist in some non-neuronal cells. CB₂ receptors are expressed mainly by immune cells, one of their roles being to alter cytokine release. ⁹-THC also appears to have non-CB₁, non-CB₂ pharmacological targets. It is already licensed for clinical use in the U.S.A. as an anti-emetic and appetite stimulant and both ⁹-THC and ⁹-THC-rich cannabis extracts show therapeutic potential as neuroprotective and anticancer agents and for the management of glaucoma, pain and various kinds of motor dysfunction associated, for example, with multiple sclerosis and spinal cord injury. CBD has much less affinity for CB₁ and CB₂ receptors than ⁹-THC and its pharmacological actions have been less well characterized. Potential clinical applications of CBD and CBD-rich cannabis extracts include the production of anti-inflammatory and neuroprotective effects, the management of epilepsy, anxiety disorders, glaucoma and nausea, and the modulation of some effects of ⁹-THC.     

狭胸天牛幼虫触角主感器及下颚须和下唇须感受器扫描电镜观察

利用扫描电镜观察了狭胸天牛幼虫触角主感器及其下颚须和下唇须顶端感受器的形态，种 类和分布，并讨论了其结构与功能的关系。结果表明，触角主感器受肾形成唇形，长约９８．０μｍ，宽约２４．５μｍ。下颚须顶端感受器２０个～２５个，下唇须顶端约１５个感受器，根据不同形态，大致分为３种类型；栓锥形，锥柱形和腔锥形。栓锥形和锥柱形感受器分别着生于下颚须和下唇须顶端表面，腔锥形感受器着生于它们的端节侧面。     

口蹄疫流行病学及感染机制的研究进展

口蹄疫(Foot-and-mouth disease FMD)是由口蹄疫病毒(Foot-and-mouth disease virus FMDV)引起偶蹄动物的一种急性、热性、高度接触性传染病。FMDV有多种血清型及其亚型,目前主要引起动物致病的就有7种,即A、O、C、SATⅠ、SATⅡ、SATⅢ和亚洲Ⅰ型(AsiaⅠ型)。病毒通常在细胞受体的参与下才入侵宿主细胞,进行扩增生命循环,感染宿主细胞,使得该病得以广泛流行。但由于口蹄疫病毒的高度变异性和适应性而在流行中出现新的特点,以及被发现的病毒在动物体内和细胞中长期存在而引发FMDV的持续感染等问题,使得本病不能有效被控制而在许多国家和地区重新暴发和流行。为此本文将口蹄疫病原学、流行病学、病毒细胞受体及其病毒在体内持续感染形成的原因方面进行的论述,为口蹄疫病毒感染机制的研究提供了科学的依据。     

成年大鼠睾丸去精索上神经对睾丸功能及肾上腺素能受体表达的影响

试验旨在研究精索上神经（superior spermatic nerve,SSN）对睾丸功能的影响,25只成年Wistar大鼠随机分为2组,试验组左右睾丸切除精索上神经,手术30 d后两组大鼠同时处死取样分析。结果显示,睾丸去精索上神经不影响睾丸指数的大小但使附睾尾精子数极显著降低（P＜0.01）,平均日增重显著增加（P＜0.05）。增殖细胞核抗原（PCNA）免疫组织化学染色结果显示,睾丸去精索上神经不影响曲细精管精原细胞和初级精母细胞的增殖,但影响曲细精管的形态和生殖细胞的规则排列。RT-PCR结果显示,睾丸去精索上神经明显上调β1AR mRNA的表达,下调β2AR mRNA的表达;另外切除精索上神经不影响睾丸3β-羟胆固醇脱氢酶（3β-HSD）mRNA表达,但显著抑制类固醇快速调节蛋白（StAR）、胆固醇侧链裂解酶（P450scc）mRNA表达（P＜0.05）。结果表明,支配睾丸的精索上神经通过调节肾上腺素能受体β1AR和β2AR的表达及StAR和P450scc影响睾丸睾酮的合成和精子的发生。     

REGIONAL BINDING INDEX OF THE RADIOLABELED SELECTIVE 5-HT2A ANTAGONIST 123I-5-I-R91150 IN THE NORMAL CANINE BRAIN IMAGED WITH SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY

The pattern of the specific 5-HT2A (5-hydroxytryptamine 2A receptor) antagonist 123I-5-I-R91150 was measured in 10 healthy dogs without neurologic and behavior abnormalities. Eight cortical regions (left and right fronto-, temporo-, parieto-, and occipitocortical area), one global subcortical region (including the thalamic system) were compared with a reference region lacking receptors; that is, the cerebellum. The 123I labeled radioligand was injected intravenously 100-200 minutes before acquisition. Both transmission and emission data were obtained with a triple head gamma camera equipped with high-resolution fanbeam collimators. The emission data were corrected for scatter and attenuation. To delineate different cerebral regions more accurately, the regions of interest (ROI) defined in a former study on brain perfusion measured with 99mTc-ethyl cysteinate dimer (ECD) in the same dogs were used. The co-registration of the 99mTc-ECD and the 123I-5-I-R91150, obtained from each dog, was realized with the help of corresponding transmission maps. By normalizing each regional cerebral activity to the activity observed in the cerebellum, the regional radioactivity (binding index) could be relatively quantified. Highest brain uptake was noted in the frontocortical brain areas (right: 1.85, left: 1.89), followed by the temporocortical region (right: 1.58, left: 1.56). Least uptake was noted in the more caudal and middle brain regions [occipito- (right: 1.46, left: 1.41), parietocortical (right: 1.30, left: 1.26), and striatal region (1.19)]. No gender nor age influence was noted in this series. The 123I labeled serotonin-2A receptor ligand seems to have similar cortical binding in the normal canine brain, as shown in humans and other animal species. A frontocortical to occipitocortical (rostrocaudal) binding index gradient was identified within the dog, which has not been seen in imaging studies from humans and other animal species. The significance of these results will need further investigation. This normative data can be used to compare regional brain uptake of the 123I-radioligand to dogs with behavioral disorders related to the serotonergic system, in future studies.     

荆豆凝集素-1受体在犬子宫内的分布与激素调节

采用组织化学方法对荆豆凝集素-1(ulex europaeus agglutinin-1,UEA-1)受体在发情周期和早期妊娠犬子宫内的分布以及激素调节进行了研究。结果显示,UEA-1受体主要存在于犬子宫内膜腔上皮和腺上皮,其表达量随妊娠阶段的不同而发生动态性变化。UEA-1受体在休情期犬子宫内未见表达,而在发情期犬子宫内膜腔上皮和腺上皮内的表达量很高。在早期妊娠犬子宫内,在妊娠第6天和12天犬子宫内的表达量较低,此后其表达量逐渐增加,在妊娠第17天时,UEA-1受体在子宫内膜腔上皮和腺上皮内的表达量达到峰值,此后其表达量又逐渐下降,在妊娠第23天时未见表达。注射雌激素可明显促进卵巢切除后犬子宫内膜UEA-1受体的表达。结果表明,犬子宫内UEA-1受体的分布与胚胎着床前胚胎与子宫内膜之间的黏附和植入有关,UEA-1受体在犬子宫内的表达受母体分泌的激素所调控。     

Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues

Steroid receptor expression was assessed by immunohistochemistry in neoplastic, hyperplastic/dysplastic, and normal mammary tissue samples removed from 68 queens and 47 bitches, using monoclonal antibodies against human oestrogen-alpha (ER) and progesterone receptors (PR). Mammary lesions were classified according to World Health Organization (WHO) criteria, and all animals with invasive carcinomas were clinically followed for 2 years. Stromal and/or lymphatic invasion and histological grading were also recorded. In both species, ER expression was significantly higher in healthy tissues, hyperplastic/dysplastic lesions, and benign tumours than in carcinomas. The loss of ER expression was more marked in feline than in canine carcinomas. In queens, PR expression increased in dysplastic lesions and "in situ" carcinomas and decreased in invasive carcinomas, even if parts of these tumours were still PR-positive. In bitches no significant variation in PR expression was observed between normal tissue, dysplasias, and benign neoplasms, but was significantly lower in carcinomas. In both species ER and PR expression in invasive carcinomas did not correlate either with histological parameters or overall survival time. This study demonstrates several differences in steroid hormone dependency between the two species. The percentage of PR-positive feline carcinomas suggests a possible role of progesterone in promoting early tumour cell growth in queens. The low percentage of ER-positive invasive carcinomas further demonstrated the aggressive phenotype and behaviour of feline mammary tumours.     

Immunohistochemical expression of progesterone receptors, growth hormone and insulin growth factor-I in feline fibroadenomatous change

The immunohistochemical expression, tissue-specific and cell-specific distribution patterns of progesterone receptors (PR), growth hormone (GH) and insulin growth factor-I (IGF-I) have been studied in 22 cases of feline fibroadenomatous change (FFAC). PR and GH were detected in all cases and were distributed homogeneously throughout the lesion, while IGF-I was detected in 77% of the cases at the site of ductal budding. The simultaneous expression of PR, GH and IGF-I was detected in epithelial cells in 14 of 22 cases while PR and GH expression only was detected in epithelial cells in 11 cases. Cases that expressed GH and IGF-I without PR expression in the stroma were the most numerous. Double immunohistochemical staining showed the co-localisation of PR and GH in a subset of ductal epithelial cells located between basal/myoepithelial and luminal cells (probably undifferentiated stem cells). These results suggest that ligand-activated progesterone receptors may induce the local synthesis of GH which in turn may exert its proliferative action directly and also indirectly through the production of other growth factors, such as IGF-I, in an autocrine/paracrine manner.